2.68
price up icon1.13%   0.03
after-market After Hours: 2.68
loading

Ventyx Biosciences Inc Stock (VTYX) Latest News

pulisher
Nov 29, 2024

Vestal Point Capital LP Purchases 410,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat

Nov 29, 2024
pulisher
Nov 29, 2024

Sio Capital Management LLC Purchases 1,193,024 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat

Nov 29, 2024
pulisher
Nov 27, 2024

Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN

Nov 27, 2024
pulisher
Nov 26, 2024

Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Whitney Tilson, Steven Cohen, Scott Bessent, Millennium Management, Paloma Partners, Ventyx Biosciences Inc (VTYX), Vistra Corp (VST), and More - Insider Monkey

Nov 26, 2024
pulisher
Nov 26, 2024

Ventyx Biosciences Inc (NASDAQ: VTYX) Jumps 11.35%, Turning Investors Away - Stocks Register

Nov 26, 2024
pulisher
Nov 25, 2024

Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock By Investing.com - Investing.com Nigeria

Nov 25, 2024
pulisher
Nov 25, 2024

Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock - Investing.com

Nov 25, 2024
pulisher
Nov 22, 2024

Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Price Target at $10.00 - MarketBeat

Nov 22, 2024
pulisher
Nov 20, 2024

Thinking about buying stock in Solid Power, Crowdstrike Holdings - GuruFocus.com

Nov 20, 2024
pulisher
Nov 19, 2024

Ventyx Biosciences stock hits 52-week low at $1.78 amid market shifts - Investing.com Australia

Nov 19, 2024
pulisher
Nov 17, 2024

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance

Nov 17, 2024
pulisher
Nov 14, 2024

We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully - Simply Wall St

Nov 14, 2024
pulisher
Nov 12, 2024

Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - The Manila Times

Nov 12, 2024
pulisher
Nov 11, 2024

Ventyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Ventyx Biosciences’ (VTYX) “Outperform” Rating Reiterated at Oppenheimer - Defense World

Nov 11, 2024
pulisher
Nov 08, 2024

Ventyx Biosciences (NASDAQ:VTYX) Given "Outperform" Rating at Oppenheimer - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress - The Manila Times

Nov 07, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha

Nov 04, 2024
pulisher
Nov 01, 2024

Thinking about buying stock in QuickLogic, Ventyx Biosciences, D - GuruFocus.com

Nov 01, 2024
pulisher
Oct 28, 2024

These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider

Oct 28, 2024
pulisher
Oct 28, 2024

Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat

Oct 28, 2024
pulisher
Oct 17, 2024

HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com

Oct 16, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire

Oct 16, 2024
pulisher
Oct 15, 2024

Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada

Oct 15, 2024
pulisher
Oct 15, 2024

VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 - The Manila Times

Oct 15, 2024
pulisher
Oct 08, 2024

Did Ventyx Biosciences Inc (VTYX) perform well in the last session? - US Post News

Oct 08, 2024
pulisher
Oct 07, 2024

An analyst sees good growth prospects for Ventyx Biosciences Inc (VTYX) - SETE News

Oct 07, 2024
pulisher
Oct 07, 2024

Sanofi Invests $27M in Ventyx Bio - San Diego Business Journal

Oct 07, 2024
pulisher
Oct 03, 2024

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

Ventyx Biosciences Inc (VTYX) may enjoy gains as insiders got busy in the recent days - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

Is Ventyx Biosciences Inc (VTYX) a good investment opportunity? - US Post News

Oct 02, 2024
pulisher
Sep 30, 2024

Gaining Ground: Ventyx Biosciences Inc (VTYX) Closes Lower at 2.31, Down -2.12 - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Take off with Ventyx Biosciences Inc (VTYX): Get ready for trading - SETE News

Sep 30, 2024
pulisher
Sep 28, 2024

VTYX Stock Rises on Strategic Equity Investment Deal With SNY - MSN

Sep 28, 2024
pulisher
Sep 26, 2024

Deerfield Management Company L.P. Series C Buys 2,287,570 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat

Sep 26, 2024
pulisher
Sep 26, 2024

Stock Surge: Ventyx Biosciences Inc (VTYX) Closes at 2.39, Marking a -2.85 Increase/Decrease - The Dwinnex

Sep 26, 2024
pulisher
Sep 26, 2024

Ventyx Biosciences, Inc. (NASDAQ:VTYX) to Post FY2024 Earnings of ($2.13) Per Share, HC Wainwright Forecasts - MarketBeat

Sep 26, 2024
pulisher
Sep 26, 2024

Sanofi’s $27 Million Investment in Ventyx Biosciences - Global Legal Chronicle

Sep 26, 2024
$21.50
price up icon 1.61%
$74.59
price down icon 1.14%
$370.49
price down icon 2.02%
$43.06
price down icon 0.76%
$215.00
price up icon 4.29%
$118.39
price down icon 1.93%
Cap:     |  Volume (24h):